• OFID 2018:5 (Suppl 1) • Poster Abstracts significantly higher among patients who died during admission than those who survived (median 6 vs. 4). A score of ≥4 was defined as severe. The performance of severity score was better than that of SHEA-IDSA or ESCMID definition (see figure) . PPV = positive predictive value; NPV = negative predictive value. Conclusion. Current guidelines use WBC, sCr increase, sCr, or albumin to define the severity of CDI. Our severity scoring system improved the predictive performance by adding novel indicators of comorbidities, BUN, BUN/sCr, and anti-diarrhea medications use.
Endemic Corridors: A Useful Tool for the Approach of
Background. Clostridium difficile infection (CDI) is a healthcare-associated infection causing morbidity, mortality, and increase in the economic burden of health. Accurate and accesible methods to predict the epidemiologic trends of CDI are scarce. The systematic collection of data contributes to the development of an endemic corridor which estimates the expected cases in a period of time, facilitating the identification of outbreaks. In Guatemala, no obligatory report is required and no national surveillance programs for CDI exist. Therefore, understanding local epidemiologic trends of CDI is important in order to make future predictions.
Methods. All consecutive primary CDI eopisodes (January 2012-December 2017) obtained from active surveillance in the surgery department were included. CDI was defined as diarrhoea and a positive stool PCR test for C. difficile toxin A and/or B. An endemic corridor was developed to describe trends. The geometric mean and a 95% confidence interval were used to calculate upper and lower limits of weekly incidence. Demographics, clinical characteristics, antimicrobial treatment, and outcome of CDI were analyzed.
Results. A total of 208 CDI episodes were included in the study (9 healthcare workers). The incidence of CDI cases increased from 12.85/1,000 discharges (2016) to 18.53/1,000 discharges (2017). CDI was higher among male (54.8%) adults (18-64 years; 72.23%). NAP1 strain was identified in 38% of all cases, with a constant increase from 2012 to 2017. All cases were treated according to guidelines. No recurrences or deaths occurred during the studied time period. The highest incidence of CDI was observed between epidemiologic weeks 7, 8, and 42. Eleven outbreaks were identified in the studied time period, the first and major outbreak occurred in 2013; 2015 had the most outbreaks with 4. Both 2016 and 2017 had threeoutbreaks each.
Conclusion. Owing to the active and systematic surveillance of CDI, an endemic corridor was created. This will be a useful tool to develop interventions according to the epidemiologic trends of local CDI. Prompt identification of cases and strict adherence to patient isolation and treatment guidelines resulted in null mortality rates despite the alarming increase in NAP1 strains.
Disclosures.All authors: No reported disclosures. Background. Clostridium difficile infection (CDI) remains a major health problem in the United States. The IDSA guidelines recommend using stool toxin assay as part of a multistep algorithm rather than nucleic acid amplification test (NAAT) alone. However, the clinical significance of toxin negative tests remains a subject of debate. We performed a prospective study in our institution to describe clinical outcomes of CDI based on the results of the stool toxin assay.
Severity and Clinical Outcomes of Clostridium difficile
Methods. Our laboratory utilizes a 2-step algorithm, using glutamate dehydrogenase plus detection of toxin B by enzyme immunoassay (EIA) arbitrated by NAAT for testing stool samples submitted for C. difficile testing. The study was conducted between January and December 2017. Patients diagnosed with CDI based on laboratory results were divided into two groups based on toxin B assay results. Shotgun metagenomics was performed directly on stool specimens using Illumina NextSeq in a subset of patients. Chart reviews were performed to assess clinical outcomes. Our primary outcome was incidence of severe CDI and 30-day mortality.
Results. A total of 2,823 samples were submitted to the laboratory for testing for suspected CDI. Three hundred thirty-eight samples in 290 discrete patients were considered positive using the two step algorithm. Whole genome sequencing was performed on samples from 57 patients (Figure 1 ). Clinical outcome data were available for 53 patients. Thirty percent were on active chemotherapy. Thirty-four patients were toxin B positive (group 1), 19 were toxin B negative (group 2) by EIA. Hospital onset disease was seen in 10 (27%) of patients in group 1 vs. 7 (37%) in group 2 (P = 0.57). Thirty-day mortality was 3% in toxin positive vs. 5% in toxin negative groups (P = 0.67). Severe CDI was seen in 14 (41%) in group 1 vs. 8 (42%) in group 2 (P = 0.94). NAP 1 strain was detected in 10.5% of patients in group 2. Percentage of C. difficile reads on sequencing in fecal samples in group 1 (0.17%) was not significantly different from group 2 (0.24%) (P = 0.70, Figure 2 ).
Conclusion.
In our cohort, detection of C. difficile toxin in stool samples was not associated with increased severity of disease. Our cohort has a higher prevalence of patients on active chemotherapy than previously studied cohorts.
Bioburden of C. difficile was not significantly different in toxin positive and negative disease. Background. There remains a paucity of data regarding optimal treatment of patients with severe Clostridium difficile infection (CDI) in the intensive care unit (ICU). Based on expert opinion, the 2018 SHEA-IDSA CDI Clinical Practice Guidelines recommend combination therapy (oral vancomycin [PO VAN] plus intravenous metronidazole [IV MDZ]) in fulminant CDI only. A 2015 study suggested a mortality benefit with combination therapy of PO VAN plus IV MDZ for ICU patients regardless of severity. The objective of this study was to determine the impact of combination therapy on clinical outcomes in ICU patients with severe CDI, compared with PO VAN monotherapy.
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Oral Vancomycin Plus Intravenous Metronidazole for Severe
Methods. Single-center, retrospective, cohort of adult patients admitted to an ICU between April 2016 and April 2018 with a positive C. difficile nucleic acid amplification test and an order for PO VAN were screened for inclusion. Patients were excluded if they had life-threatening intra-abdominal complications, including toxic megacolon/ emergent colectomy. The primary outcome was 30-day in-hospital all-cause mortality. In a subgroup analysis, patients were matched using Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Logistic regression was conducted to identify clinical variables associated with mortality.
Results. One hundred one patients were included; 47 received combination therapy with IV MDZ. Baseline characteristics were similar across groups, except patients in the IV MDZ group had a higher median white blood cell (WBC) count at diagnosis (18.4 vs. 13.9, P = 0.023) and were more likely to receive a higher dose (500 mg) of PO VAN (36.2% vs. 7 .4%, P < 0.0001). Thirty-day mortality was 14.9% in the combination group vs. 7.4% in the monotherapy group, (P = 0.338). APACHE II Score was the only variable independently associated with 30-day mortality (OR = 1.13, 95% CI 1.03 -1.24). There was no difference in probability of receiving IV MDZ based on APACHE II score. In a subgroup of patients matched by APACHE II score (n = 76), mortality remained nonsignificantly different (15.8% vs. 9.7%, P = 0.480).
Conclusion. Our data question the utility of IV MDZ in addition to PO VAN for ICU patients with severe CDI. There remains a possibility for confounding by indication in this retrospective analysis.
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